抗 CD22/CD19 CAR-T 细胞疗法 CART2219.1 在成人和儿童复发/难治性 B-ALL 中的 I/II 期试验
A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.
在一项多中心I/II期试验中,所有患者(n=11;7名儿童,4名成人)在第28天均达到完全缓解(91%为微小残留病阴性)。
英文原题:Full-Length Immune Repertoire Reconstruction and Profiling at the Transcriptome Level Using Long-Read Sequencing.
FLIRseq 能够对直接 V(D)J 重排和免疫球蛋白类别进行无偏倚且全面的分析,从而有助于表征致病机制、监测微小残留病以及定制过继性细胞治疗。
由于免疫组库(IR)的多样性,使用传统短读长测序重建全长IR已被证明具有挑战性。
开发了一种全长IR测序(FLIRseq)工作流程,采用线性滚环扩增和纳米孔测序。其准确性和定量能力通过质粒混合物和基于短读长的商业化B细胞受体/T细胞受体测序(BCR/TCR-seq)进行了验证。使用FLIRseq分析了8例急性淋巴细胞白血病患者、3例过敏性疾病患者、4例银屑病患者和5例前列腺癌患者组织及外周血中的IR。
FLIRseq读长的错配率和缺口率低于nanopore读长,而识别率高于nanopore读长(均P < 2.2 × -16)。FLIRseq对组分的相对定量与实际定量一致(P > 0.05)。FLIRseq优于BCR/TCR-seq,提供了长的互补决定区3、B细胞同种型和很少使用的V基因序列。FLIRseq观察到缓解期白血病患者的克隆型多样性增加(P < 0.05),异常BCR/TCR的百分比降低。对于过敏性疾病或银屑病患者,FLIRseq提供了对V(D)J重排和特定免疫球蛋白类别的直接见解。与前列腺癌组织相比,银屑病组织淋巴细胞中偏倚T细胞受体β链的全长V片段显示出与AlphaFold2预测的蛋白质结构更一致(P < 0.05)。
BACKGROUND: Due to the diversity of the immune repertoire (IR), reconstructing full-length IR using traditional short-read sequencing has proven challenging. METHODS: A full-length IR sequencing (FLIRseq) work flow was developed with linear rolling circle amplification and nanopore sequencing. Its accuracy and quantification ability were verified by plasmid mixtures and commercial B-cell receptor/T-cell receptor sequencing (BCR/TCR-seq) based on short reads. IRs in tissues and the peripheral blood from 8 patients with acute lymphoblastic leukemia, 3 patients with allergic diseases, 4 patients with psoriasis, and 5 patients with prostate cancer were analyzed using FLIRseq. RESULTS: FLIRseq reads had lower mismatch rates and gap rates, and higher identify rates than nanopore reads (all P < 2.2 × -16). The relative quantification of components by FLIRseq was consistent with the actual quantification (P > 0.05). FLIRseq had superiority over BCR/TCR-seq, providing the long complementarity-determining region 3, B-cell isotype, and the rarely used V gene sequence. FLIRseq observed an increase in clonotype diversity (P < 0.05) and a decrease in the percentage of abnormal BCRs/TCRs in patients with leukemia in remission. For patients with allergic diseases or psoriasis, FLIRseq provided direct insights into V(D)J recombination and specific immunoglobulin classes. Compared with that in prostate cancer tissues, the full-length V segment of the biased T-cell receptor β chain from lymphocytes in psoriatic tissues showed a more consistent AlphaFold2-predicted protein structure (P < 0.05). CONCLUSIONS: FLIRseq enables unbiased and comprehensive analyses of direct V(D)J recombination and immunoglobulin classes, thereby contributing to characterizing pathogenic mechanisms, monitoring minimal residual disease, and customizing adoptive cell therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。